secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2024-04-08T23:59:59+00:00
Accession:  0001140361-24-018449
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis Phase 3 Balance study of olezarsen meets primary endpoint; reduces acute pancreatitis in FCS
--------------------------------------------------------------------------------

- Olezarsen 80 mg reduced fasting triglycerides by 44% vs placebo at 6 months (p<0.001).
- Acute pancreatitis events: 1 event in 80 mg group vs 11 in placebo over 12 months.
- All-cause hospitalizations reduced by 84% (placebo-adjusted) from baseline to 12 months.
- No serious treatment-emergent AEs related to olezarsen; serious AEs 14% (80 mg) vs 39% placebo.
- Ionis to pursue regulatory approval for first potential FCS treatment in U.S.; data published in NEJM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036124018449/0001140361-24-018449-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036124018449/ef20026226_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-018449

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer